{"id":"https://openalex.org/W2567652142","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","title":"Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.","display_name":"Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2567652142","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","mag":"2567652142"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.7550","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057281549","display_name":"Anne S. Tsao","orcid":"https://orcid.org/0000-0003-0505-6639","observed_orcids":["https://orcid.org/0000-0003-0505-6639"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. S. Tsao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020305963","display_name":"S. Liu","orcid":"https://orcid.org/0009-0000-3388-6280","observed_orcids":["https://orcid.org/0009-0000-3388-6280"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087876756","display_name":"J. J. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014225996","display_name":"Christine M. Alden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. M. Alden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078483387","display_name":"E. S. Kim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. S. Kim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108569702","display_name":"G. R. Blumenschein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. R. Blumenschein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. S. Herbst","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111435637","display_name":"Scott M. Lippman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. M. Lippman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028085268","display_name":"Ignacio Ivan Wistuba","orcid":"https://orcid.org/0000-0003-3365-6340","observed_orcids":["https://orcid.org/0000-0003-3365-6340"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. I. Wistuba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111144617","display_name":"Waun Ki Hong","orcid":"https://orcid.org/0009-0008-9329-5544","observed_orcids":["https://orcid.org/0009-0008-9329-5544"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. K. Hong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"7550","last_page":"7550"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8820000290870667},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.9670000076293945},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9819999933242798},{"id":"https://openalex.org/keywords/vandetanib","display_name":"vandetanib","score":0.9359999895095825},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/bexarotene","display_name":"bexarotene","score":0.9940000176429749},{"id":"https://openalex.org/keywords/age-subgroup-analysis","display_name":"age subgroup analysis","score":0.6060000061988831},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.6830000281333923},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.781000018119812},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.781000018119812},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.8790000081062317},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7620000243186951},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4350000023841858},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9228173494338989},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6711100935935974},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6041644811630249},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.48314210772514343},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4735904335975647},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4500194787979126},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.4252532124519348},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35571151971817017},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.31503570079803467},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30268508195877075},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.7550","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7550","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1965355592","https://openalex.org/W2263261514","https://openalex.org/W1969116196","https://openalex.org/W4242303997","https://openalex.org/W2115697715","https://openalex.org/W2570463002","https://openalex.org/W2787601918","https://openalex.org/W2567366645","https://openalex.org/W2612042782","https://openalex.org/W2246516047"],"abstract_inverted_index":{"7550":[0],"Background:":[1],"BATTLE":[2,43],"was":[3,113,206,294,322,356],"a":[4,250,280,312],"phase":[5],"II":[6],"trial":[7,44],"that":[8,240,321],"randomized":[9,74],"255":[10],"patients":[11,364],"(pts)":[12],"into":[13],"4":[14],"separate":[15],"trials:":[16],"erlotinib":[17],"(E),":[18],"erlotinib-bexarotene":[19],"(E-B),":[20],"vandetanib":[21],"(V),":[22],"and":[23,60,140,146,216,228,266,336,343],"sorafenib":[24],"(S).":[25],"Treating":[26],"elderly":[27,362],"chemo-refractory":[28],"NSCLC":[29,55,363],"pts":[30,40,56,72,255,329],"is":[31,374],"often":[32],"challenging;":[33],"we":[34],"sought":[35],"to":[36,75,333,350,391],"determine":[37],"if":[38],"older":[39,209,241,382,401],"on":[41,378],"the":[42,156,298],"had":[45,234,249,259,279,311],"worse":[46,281],"outcomes":[47],"or":[48,93,193],"more":[49,331,348],"adverse":[50,376],"events":[51],"(AE).":[52],"Methods:":[53],"Chemorefractory":[54],"with":[57,78,99,247,263,270,283,325],"PS":[58,181,184,187],"0-2":[59],"any":[61,198],"line":[62],"of":[63,315],"prior":[64],"therapy":[65,77,371],"were":[66,73,105,151,195,330,347,398],"enrolled.":[67],"Following":[68],"tumor":[69],"biomarker":[70],"evaluation,":[71],"oral":[76],"E":[79,83,264],"(150":[80],"mg":[81,91,96],"daily),":[82,88,92],"+":[84],"B":[85],"(400":[86,95],"mg/m2":[87],"V":[89,248,284],"(300":[90],"S":[94,271,326],"twice":[97],"daily)":[98],"Q8":[100],"wk":[101],"radiographic":[102],"assessment.":[103],"AE":[104,319],"assessed":[106],"by":[107],"NCI-CTC":[108],"v.":[109],"3.0.":[110],"Subgroup":[111],"analysis":[112],"conducted":[114],"via":[115],"Fisher\u2019s":[116],"exact":[117],"test":[118],"for":[119,368],"age":[120,160,165,169,172,199,212,275,299,340,344],"groups":[121,300],"(\u2265":[122],"65":[123,126,219,225,244,309,342,385],"v":[124,130,135],">":[125,136,175],"years;":[127,132],"\u2265":[128,133,211,218,224,230,243,256,276,308,341,345,384],"70":[129,131,176,213,231,257,277,346],"75":[134,137],"years),":[138],"treatments,":[139],"gender.":[141],"Kaplan-Meier":[142],"method,":[143],"log-rank":[144],"tests,":[145],"Cox":[147],"proportional":[148],"hazards":[149],"models":[150],"also":[152],"used.":[153],"Results:":[154],"In":[155],"ITT":[157],"population,":[158],"median":[159],"62":[161],"(range":[162],"26-84);":[163],"16%":[164],"\u2264":[166],"50,":[167],"29%":[168],"51-60,":[170],"34%":[171],"61-70,":[173],"22%":[174],"yrs;":[177],"46%":[178],"F,":[179],"9%":[180],"0,":[182],"77%":[183],"1,":[185],"14%":[186],"2.":[188],"No":[189],"differences":[190,395],"in":[191,208,289,301,380,396,400],"RR":[192],"OS":[194,269],"seen":[196,324,399],"between":[197,297],"groups.":[200],"However":[201],"DCR":[202,262,290],"at":[203],"8":[204],"wks":[205],"better":[207,235,251],"women":[210,274],"yrs":[214,220,226,232,245,258,278,310,386],"(p=0.06)":[215],"men":[217,223,229,242,383],"(p=0.008);":[221],"also,":[222],"(p=0.0068)":[227],"(p=0.09)":[233],"PFS.":[236],"Treatment-specific":[237],"analyses":[238],"showed":[239],"treated":[246],"PFS":[252,282],"(p=0.03).":[253],"Male":[254],"an":[260,267],"improved":[261,268],"(p=0.05)":[265,320],"(p=0.04).":[272,327],"However,":[273,306],"(p=0.03)":[285],"but":[286,354],"no":[287,295,375],"difference":[288,296],"nor":[291],"OS.":[292],"There":[293],"grade":[302,316],"3-4":[303,317],"heme":[304],"AE.":[305],"Women":[307,339],"higher":[313],"rate":[314],"non-heme":[318],"primarily":[323],"Older":[328],"likely":[332,349],"report":[334],"diarrhea":[335],"GI":[337],"symptoms.":[338],"require":[351],"dose":[352],"reductions":[353],"this":[355],"not":[357],"treatment":[358],"specific.":[359],"Conclusions:":[360],"Fit":[361],"should":[365],"be":[366],"considered":[367],"salvage":[369],"targeted":[370],"as":[372],"there":[373],"impact":[377],"survival;":[379],"fact,":[381],"derive":[387],"significant":[388],"clinical":[389],"benefit":[390],"certain":[392],"agents.":[393],"Gender":[394],"tolerance":[397],"women.":[402]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-01-06T00:00:00"}